Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
98 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Phase 1/2 Recruiting
74 enrolled
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
225 enrolled
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Phase 1/2 Recruiting
107 enrolled
TRIDENT-1
Phase 1/2 Recruiting
500 enrolled 5 FDA
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Phase 1/2 Recruiting
99 enrolled
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Phase 1/2 Recruiting
63 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Phase 1/2 Recruiting
39 enrolled
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Phase 1/2 Recruiting
60 enrolled
Evaluate the Safety and Clinical Activity of HH2853
Phase 1/2 Recruiting
254 enrolled
ADCElerate1
Phase 1/2 Recruiting
270 enrolled
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Phase 1/2 Recruiting
139 enrolled
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase 1/2 Recruiting
112 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/2 Recruiting
75 enrolled
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
30 enrolled
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 Recruiting
3 enrolled
PHANTOM
Phase 1/2 Recruiting
26 enrolled
BAH2573-103
Phase 1/2 Recruiting
60 enrolled
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
Phase 1/2 Recruiting
67 enrolled
HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
150 enrolled
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
250 enrolled
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1/2 Recruiting
358 enrolled
A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma
Phase 1/2 Recruiting
65 enrolled
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Phase 1/2 Recruiting
100 enrolled
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Phase 1/2 Recruiting
200 enrolled
TRASTS
Phase 1/2 Recruiting
199 enrolled